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Resource allocation and the burden of
co-morbidities among patients diagnosed
with chronic obstructive pulmonary
disease: an observational cohort study from
Danish general practice
Peder Ahnfeldt-Mollerup1*, Jesper Lykkegaard1, Anders Halling1,3, Kim Rose Olsen1,2 and Troels Kristensen1,2
Abstract
Background: Chronic obstructive pulmonary disease is a leading cause of mortality, and associated with increased
healthcare utilization and healthcare expenditure. In several countries, morbidity-based systems have changed the
way resources are allocated in general practice. In primary care, fee-for-services tariffs are often based on political
negotiation rather than costing systems. The potential for comprehensive measures of patient morbidity to explain
variation in negotiated expenditures for patients with chronic obstructive pulmonary disease has not previously
been examined. The aim of this study is to analyze fee-for-service expenditure of patients diagnosed with chronic
obstructive pulmonary disease visiting Danish general practice clinics and further to assess what proportion of
fee-for-service expenditure variation was explained by patient morbidity and general practice clinic
characteristics, respectively.
Methods: We used patient morbidity characteristics such as diagnostic markers and multi-morbidity adjustment
based on adjusted clinical groups (ACGs) and fee-for-service expenditure for a sample of primary care patients for the
year 2010. Our sample included 3,973 patients in 59 general practices. We used a multi-level approach.
Results: The average annual fee-for-service expenditure of caring for patients diagnosed with chronic obstructive
pulmonary disease in general practice was about EUR 400 per patient. Variation in the expenditures was driven by
multimorbidity characteristics up to 28 % where as characteristics such as age and gender only explained 5 %.
Expenditures increased progressively with the degree of multimorbidity. In addition, expenditures were higher for
patients who had diagnostic markers based on ICPC-2 (body systems and/or components such as infections and
symptoms). Nevertheless, 9.8–15.4 % of the variation in expenditure was related to the clinic in which the patient was
cared for.
Conclusion: Patient morbidity and general practice clinic characteristics are significant patient-related fee-for-service
expenditure drivers in chronic obstructive pulmonary disease care.
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Background
The association between chronic obstructive pulmonary
disease (COPD) and healthcare utilization along with
health care expenditure is substantial [1–4]. Overall, the
increasing incidence and prevalence of COPD contribute
to an increased pressure on the healthcare sector includ-
ing general practice [5]. In the primary care sector it is
the responsibility of general practitioners (GPs) to diag-
nose, treat and follow up on patients, including patients
with relatively complicated and chronic diseases, e.g.
COPD [6]. COPD is associated with a high degree of co-
morbidity from other chronic diseases [7, 8], which con-
tributes to its high clinical and economic burden.
Previous evidence has revealed specific multimorbid
pairs to be associated with different levels of healthcare
transitions and expenditures or costs, and identification
of multi-morbidity type and linkage of information
across healthcare interfaces provide opportunities for
targeted intervention and delivery of cost-effective inte-
grated care [9]. Lack of morbidity-adjusted remuneration
among GPs and a dominant fee-for-service (FFS) com-
ponent may lead to short GP visits focused on one prob-
lem [10]. The average patient diagnosed with COPD
with comorbidities may not come back to the GP over
and over again in a way that reflects their healthcare
need.
The aims of this study are to analyze FFS expenditure
of patients diagnosed with COPD visiting Danish GP
clinics, and to assess what proportion of FFS expend-
iture variation was explained by patient comorbidity and
GP clinic characteristics, respectively.
Context and data
GP setting and remuneration
In Denmark there is a national health insurance
scheme covering all patients, and the majority of GP
services are free of charge. GPs act as gatekeepers to
the rest of the healthcare system. The GPs are com-
pensated by the national health insurance scheme
through a combination of per capita fees (30 %) and
FFS (70 %). The expenditures for the health insurance
scheme for FFS covers a fee for each service such as
an office visit, test, clinical or diagnostic procedure,
or other healthcare services. For a set of eight speci-
fied chronic diseases, including COPD, an annual
checkup at the GP is expected, where the treatment
plan is reevaluated, preventive measures taken into
account and the patient’s psychosocial problems dis-
cussed. For this annual checkup there is a special fee,
which is higher than the standard fee for surgery visit.
Several countries with publicly funded general prac-
tice clinics have reoriented their remuneration sys-
tems towards a morbidity-based casemix adjustment
system [11]. Denmark has yet to reorient its resource
allocation system in the general practice sector towards
morbidity-based casemix systems [12]. However, there
seems to be a tendency or willingness to change the
current system in the direction of a morbidity-based sys-
tem, where a larger component is based on needs rather
than the volume of visits [13].
Classification and grouping of diagnosis
John Hopkins adjusted clinical groups (ACG) system is
based on age, sex and mix of diagnoses [14, 15]. The
number of visits is not included. It measures an individ-
ual’s health status and risk of health service use and has
demonstrated that it is robust in its ability to measure
morbidity burdens in individuals and populations [11, 16].
Denmark has recently introduced systems that could po-
tentially allow such a system. Danish GPs have begun to
use International Classification of Primary Care coding
(ICPC-2) and the Danish Quality Unit of General Practice
(DAK-E) has implemented automatic electronic web-
based collection of ICPC-2 diagnoses for episodes of care
and quality of care parameters from GP clinics [17]. These
data are stored in a general practice database called
DAMD. In 2008, an extended version of the ICPC-2 has
been developed and implemented in the Danish general
practice sector under the name ICPC-2-DK. This version
is able to convert all diagnoses sent electronically from the
secondary health sector (using ICD-10 – International
Classification of Diseases 10) to be automatically imple-
mented in the GP clinic IT system, ensuring a possibility
for the GPs to create coherent and coordinated care
across the healthcare sectors.
These new and unique data offer an opportunity to
examine the relationship between current FFS expendi-
tures and patient resource utilization, morbidity and re-
lated GP clinic characteristics. To simplify things, the
ACG System Software assigns each patient into a six-
level morbidity category termed a Resource Utilization
Bands (RUB). The six RUBs (non-users; healthy users;
low morbidity; moderate; high; and very high) are
formed by categorizing the mutually exclusive ACG as-
signments that measure overall morbidity burden from a
period of time [18].
Ethics
The study was performed according to national and
international ethical guidelines and legislation. Prior to
the initiation of the study registration and approval from
at the Danish Data Protection Agency was obtained.
Danish legislation requires an approval from Medical
Ethical Committee only for biomedical research, and as
this study is based on data from registers no approval
from the Medical Ethical Committee was needed.
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Methods
This is an observational, retrospective, cohort study con-
ducted to assess healthcare resource utilization and ex-
penditure among patients diagnosed with COPD and
comorbidity. In 2010, the DAMD database contained
medical and pharmacy data from 59 different GP clinics
coding more than 70 % of all face-to-face encounters.
These data encompassing 141 GPs and 3,973 patients di-
agnosed with COPD were used as the data source for
this study. The medical and eligibility component files
from this database were utilized, identifying patient diag-
noses and procedures, and demographic characteristics.
All data were fully de-identified and compliant with the
legal requirements.
Outcome measures
COPD-related resource utilization and expenditures
were calculated for patients who had a registered contact
with their GP during 2010 and had the diagnosis of
COPD. For the diagnosis of COPD the ICPC-2 coding
was used, using R79, R95 and R96 listed in chapter R
(Respiratory). The examined outcomes were all cause-
and COPD-related expenditures.
Analysis
We applied a two-stage multi-level regression approach
to describe and analyze the extent to which negotiated
patient-level FFS expenditures are associated with COPD
patients’ co-morbidity burden [18–20].
In our first stage analysis we postulated that FFS ex-
penditure at the patient level was associated with demo-
graphics, patient morbidity measures and related GP
clinic characteristics. Thus we assessed whether the FFS
system prompts the GPs to provide services according
to morbidity burden. Our dependent variable was de-
fined as the total annual expenditures for the FFS remu-
neration of each patient diagnosed with COPD. In the
first stage of our analysis we applied a fixed-effects data
model that recognizes the stratification of patients
within GP clinics. The GP clinic fixed effect captures the
clinic specific relative expenditures (fixed effects) after
allowing for differences in patient characteristics.
To explore the sensitivity of results to different
morbidity and diagnostic characteristics we specified
six fixed effect models with different combinations of
four subsets of covariates: the age and gender of the
patient, the groupings of ACGs into RUBs and a set
of diagnostic markers based on ICPC-2, and number
of visit to the GP.
As COPD is the index condition this diagnosis is not
included in the RUBs. To measure the prevalence of
diagnostic markers per patient in each of the ICPC-2
classifications, and to measure the variation explained by
co-morbidity and morbidity rather than volume, we
limited our analysis to the range of different diagnoses
per patient (i.e., we excluded the volume of diagnosis to
be able to explore the explanatory power of co-
morbidity characteristics).
Gender and age have been widely applied to explain
expenditure variation. Similar to the rest of the popula-
tion female patients diagnosed with COPD are consid-
ered to more aware of their health [21, 22] and older
patients are expected to be more expensive [23]. We in-
cluded dummy variables identifying whether the patient
received care for other conditions during 2010. The ex-
pectation was that the expenditure of caring for COPD
patients would be higher for patients suffering from co-
morbidities. For such patients FFS expenditure were
expected to increase progressively with the degree and
extend of co-morbidities. In the regression we excluded
RUB0 as a reference group for RUB1-5.
Second stage analysis, after controlling for patient
characteristics, we regressed the estimated fixed effects
against a set of GP clinic characteristics to reveal the ex-
tent to which the GP-specific FFS expenditure variation
was explained by observable GP clinic characteristics.
We included the number of GP per clinic and number
of patients enrolled per GP per clinic. This based on the
supposition that if there were economies of scale [24]
due to revenue economics then the annual expenditures
per patient with COPD would increase as the size of the
clinic in terms of number of GPs increased. We also
controlled for the average physician age, the proportion
of female physicians, the proportion of patient sex and
patient age proportions, because FFS expenditure might
be influenced by these clinic characteristics [25–27]. Fi-
nally, we explored whether the GP clinic fixed effects
were associated with the proportion of co-morbidity
(RUBs) and proportions of specific diagnostic markers.
All analyses were performed with the use of the software
package STATA version 12.0 (Stata Corp., College
Station, TX, USA).
Results
Descriptive patient and clinic characteristics
Table 1 shows the expenditures per patient and non-
diagnostic markers for the dataset, for patients diagnosed
with COPD.
The figures contain three subsets of the proportions of
patient comorbidity characteristics for patients diag-
nosed with COPD: Fig. 1 shows comorbidity markers
based on RUB, Fig. 2 reveals the pattern of diagnostic
markers based on ICPC-2 chapters, and Fig. 3 includes
diagnostic chapter component markers.
The most prevalent body system marker is ‘Cardiovas-
cular’. In line with the classification of patients into
ACGs and RUBs Fig. 2 reveals that a higher RUB-level
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(RUB2-RUB5) implies a higher prevalence of comorbidi-
ties in patients with COPD.
Patients with COPD at all RUB-levels (RUB1-RUB5)
have received a mixture of chapter component markers
besides a very small prevalence of congenital anomalies.
The most prevalent COPD diagnostic markers are other
diagnoses, symptoms/complaints and infections.
Figure 4 shows that patients with COPD had pro-
gressively increasing expenditure and variation with
increasing level of RUB. More COPD comorbidities
and other independent conditions imply higher annual
expenditures. The mean (median) annual expenditures
of general practice for people with multi-morbidity
RUB0-5 were €139.0 (117.3), €189.6 (166.0), €272.2
(227.5) €388.5 (328.5), €531.8 (462.2) and €547.5
(492.0), respectively. This pattern is consistent with
the evidence behind RUBs [18]. However, more than the
descriptive statistics in Fig. 4 are needed to analyze the
relative explanatory power of RUBs.
The tariff agreement on GP services and the National
Health Service disbursement codes were used to calcu-
late expenditure data and map service for each patient
in 2010. Thus, we were able to identify the specific GP
expenditures of patients diagnosed with COPD for 2010.
Figure 5 plots these expenditures for each GP practice,
thus the y-axis showing the expenditures for patients
with COPD in each of the 59 GP clinics on the x-axis.
Table 2 displays the results of applying the five specifi-
cations that include different sets of COPD patient
markers (demographic, multimorbidity-casemix and two
sets of diagnostic characteristics). Almost all markers
were significant expenditure drivers. These models are
able to explain upwards 13.3–79.3 % of the variation in
the FFS expenditures for primary care patients in the
GP clinics, as indicated by the overall R2 statistics.
Model 1 includes demographic case mix adjusters, and
models 2–5 differ according to combinations of three
sets of morbidity-based case mix adjusters and diagnos-
tic markers: (1) RUB case mix adjusters, (2) diagnostic
markers based on ICPC-2 body system chapters ‘A–Z’,
and (3) diagnostic markers based on ICPC-2 chapter
components. Finally, model 6 incorporates the number
of visits per patient and the number of diagnoses per
patient.
Demographic markers
Model 1 shows that age and sex explained 5.1 % of the
variation in FFS expenditures. For women, primary care
expenditures were higher than for men in all models ex-
cept for model 5.
RUB markers
The inclusion of morbidity-based case mix adjusters
(RUBs) in model 2 increased the model’s explanatory
power from 5.1 to 18.1 %. Overall, FFS expenditures in-
creased progressively with the degree of comorbidity.
The coefficients for the RUBs were all related to the ref-
erence group RUB0. The expenditures for patients allo-
cated to RUB1–5 were significantly higher than for
patients allocated to RUB0. In models 3–6, the RUB co-
efficient decreased due to the introduction of additional
morbidity characteristics (ICPC-2 chapter and compo-
nent markers).
Table 1 Primary care provider and patient characteristics
Mean sd p5 p50 p95
Expenditures in Euro per patient 306.70 84.63 194.25 297.31 481.31
Non-diagnostic characteristics
Number of GPs 2.39 1.5 1.0 2.0 6.0
Age of GPs 53.57 7.67 42.00 53.67 66.00
Proportion of female GPs 0.51 0.35 0.0 0.5 1.0
Patient sex (proportion female) 0.58 0.09 0.42 0.57 0.72
Patient age (proportion 40–67) 0.56 0.11 0.40 0.56 0.76
Patient age (proportion 68+) 0.45 0.11 0.24 0.44 0.61
Number of patients 67.3
Number of diagnoses 761.2
Number of visits 525.0
Number of diagnoses per visit 1.49 0.66 0.82 1.29 3.14
Number of visits per patient 7.59 1.98 5.13 7.43 11.84
P5, 5 percent percentile, P50, 50 percent percentile, P95, 95 percent percentile
Fig. 1 Comorbidity markers based on RUB for patients diagnosed
with COPD
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Diagnostic markers: ICPC and Chapter component
Models 3–5 include combinations of the two sets of
diagnostic markers, ‘ICPC-2 Chapter Markers’ and
‘Chapter Component Markers’, and show high levels of
significant explanatory power for each of the markers.
The explanatory power (R2 - overall) increases from
18.1 to 28.1 % (model 3), 22.2 % (model 4) and 28.5 %
(model 5). The most expensive diagnostic marker for pa-
tients diagnosed with COPD seems to be endocrine/
metabolic conditions followed by conditions related to
urinary pathways, psychological or psychiatric conditions
and cardiovascular diseases. By contrast, the chapter
Fig. 2 Pattern of diagnostic markers for comorbidity based on ICPC-2 chapters
Fig. 3 Pattern of diagnostic chapter component markers for COPD
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markers for ophthalmic diseases and ear-nose-throat dis-
eases appear to be the least expensive among patients
with COPD treated in GP clinics, but these problems are
usually taken care of by specialist where no referral from
GPs is needed.
Volume markers
The inclusion of the number of visits and the number of
diagnoses in model 6 increased the explanatory power
from 28.5 to 71.2 % and changed the sign and magnitude
of several covariates, and some became insignificant.
Fig. 4 Expenditure and variation for each RUB for patients diagnosed with COPD
Fig. 5 Variation between general practice clinics for expenditures for patients diagnosed with COPD
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Table 2 First stage estimates: Variation in FFSE due to COPD patient characteristics and GP clinic fixed effect
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Demographic markers
Age of patients with COPD 4.38*** 3.03*** 2.51*** 2.85*** 2.50*** 1.82***
Proportion of female patients 25.34** 13.92 0.64 2.89 -1.10 0.43
RUB proportions
RUB 1 64.92*** -1.29 -22.41* -13.20 2.352
RUB 2 128.3*** 6.38 9.50 -7.25 16.57
RUB 3 254.8*** 38.42** 97.13*** 23.77 27.52*
RUB 4 398.3*** 104.1*** 206.4*** 84.11** 18.51
RUB 5 420.5*** 76.03 222.5*** 58.83 40.38
ICPC-2 chapter proportions
A General and unspecified 53.44*** 36.36*** 4.38
B Blood/immune system 29.38 27.03 -0.66
D Digestive 53.68*** 51.86*** 2.16
F Eye 24.29 15.48 -3.41
H Ear 36.30* 30.57* -3.12
K Cardiovascular 74.37*** 71.82*** 23.20**
L Musculoskeletal 27.26*** 20.17* -22.65***
N Neurological 51.12*** 48.71*** 9.77
P Psychological 74.71*** 72.18*** 35.59***
R Respiratory 62.57*** 48.76*** 7.85
S Skin 55.55*** 39.59*** -5.25
T Endocrine/Metabolic and Nutritional 126.8*** 123.5*** 65.07***
U Urological 78.89*** 70.55*** 16.80
W Pregnancy and Family Planning 46.34 44.86 22.53
X Female Genital 17.39 12.11 -9.62
Y Male genital 16.00 15.63 -7.82
Z Social Problems 63.65* 67.70* 11.07
ICPC-2 chapter component proportions
Process codes 53.80*** 21.35 9.28
Symptoms/complaints 52.13*** 11.05 1.11
Infections 76.93*** 28.49*** 4.56
Neoplasms -1.04 -2.41 4.39
Injuries 57.94*** 37.74*** 7.41
Congenital anomalies 17.80 1.04 6.64
Other diagnoses 79.75*** 13.32 -4.08
Volume markers
Number of visits 21.64***
Number of diagnoses 4.04**
Constant 11.22 -84.83*** -70.89*** -85.57*** -69.65** -73.62***
N 3973 3973 3973 3973 3973 3973
Sigma u 75.13 72.86 81.27 70.64 76.95 51.22
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The changed signs and magnitude of the beta coeffi-
cients in model 6 reflect the fact that some patients’
morbidity characteristics are associated with higher or
lower FFS expenditure after controlling for the volume
of activity. For instance, musculoskeletal condition
marker leads to significantly lower expenditures per pa-
tient, and endocrine/metabolic conditions and psycho-
logical or psychiatric condition markers seem to result
in larger expenditure per patient. After adjusting for the
patient characteristics, the rho statistics in Table 2 indi-
cated that GP clinic characteristics explained 9.8–15.4 %
of the remaining variation in patient expenditures. Pair-
wise likelihood ratio tests of all combinations of the
nested models (1–6) rejected all special cases in favor of
model 6. In addition, model 6 was the model with the
smallest AIC value.
Variation in GP clinic fixed effects due to GP clinic
characteristics (stage 2)
Table 3: In all five models, the number of GPs was sig-
nificant in explaining why FFS expenditures per patient
differ from one GP clinic to another. A higher number
of physicians lead to more expenditures per patient. This
finding suggests that larger clinics have larger expendi-
tures per patient. It is also evident that expenditures did
not vary from one clinic to another because of differ-
ences in the average physician age. A higher average
physician age did not lead to more expenditure per pa-
tient. Models 6A–6E show that these results were robust
to different combinations of covariates.
Discussion
The average FFS expenditures for patients diagnosed
with COPD in primary care were € 306.70. In compari-
son the average FFS expenditures for any primary care
patient including patients with chronic conditions in
2010 were € 145.6 [23]. Overall we found that age, gen-
der, RUBs and comorbidity characteristics can explain
5–28 % of the variance in FFS expenditure for the
present sample of patients with COPD in general prac-
tice. This evidence, when compared with the 5.1 % ob-
tained when only age and gender are used, indicates that
comorbidity characteristics are more powerful in explain-
ing variation in the total annual FFS for patients diagnosed
with COPD in the selected GP clinics. The comorbidity
casemix index, RUB, explained approximately 18 % of the
variation. However, two sets of diagnostic markers indi-
cate that expenditures are driven over and above by their
RUB (morbidity measures). ICPC2-chapters (body-system
& problem areas) and ICPC2-chapter component markers
both increased the explanatory power of the models
(model 2 - model 5). A total of 9.8–15.4 % of the variation
was explained by the clinic characteristics captured in
provider-specific fixed effects. When the number of visits
and diagnoses were included in model 6 the explanatory
power increased from 28.5 to 71.2 %.
The significance of the number of visits is consistent
with the fact that the standard fee for a visit is by far the
most frequently used fee, and the number of visits is by
far the most powerful co-variate accounting for 42.7 %
of the variation in FFS expenditure. However, the results
indicate significantly higher expenditure for psycho-
logical or psychiatric and endocrine/metabolic condi-
tions. The latter confirms that patients diagnosed with
diabetes and psychiatric diseases allow for specific and
supplementary fees (and lower for cardiovascular and
musculoskeletal conditions).
Clinic characteristics: Different clinics have different
expenditures for patients diagnosed with COPD. A
higher number of GPs per clinic tend to have higher ex-
penditure. This indicates that larger GP clinics may be
able to exploit economies of scale with respect to ex-
penditure. This may be due to better organization of the
clinic and the possibility to employ clinical staff like
nurses, laboratory technicians, etc. that can increase the
total service and thus increase expenditure [28]. An al-
ternative explanation is that too many cooks spoil the
broth, meaning that larger clinics with more GPs patient
risk to consult a different GP from time to time and the
lack of continuity and personal knowledge of the patient
might results in more visits to the clinic leading to an
increase in expenditure. Only 9.8–15.4 % of the variation
could be explained by clinic characteristics. Whereas the
former result indicates some association between re-
source use (RUB) and FFS expenditures, the latter indi-
cates that, even if GP clinics manage patients in different
ways, the selected clinic characteristics have limited ef-
fects on FFS expenditures.
FFS is a payment model where services are unbundled
and paid for separately. In health care it gives an
Table 2 First stage estimates: Variation in FFSE due to COPD patient characteristics and GP clinic fixed effect (Continued)
Sigma e 227.9 207.2 188.8 200.3 188.3 120.1
rho 0.0980 0.110 0.156 0.111 0.143 0.154
r2 o 0.0507 0.181 0.281 0.222 0.285 0.712
N g 59 59 59 59 59 59
* p < 0.05, ** p < 0.01, *** p < 0.001. r2 o = Explanatory power
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Table 3 Second stage estimations - expenditure variation due to provider characteristics
Model 6A Model 6B Model 6C Model 6D Model 6E
Non-diagnostic markers
No. of GPs 12.19*** 11.71*** 11.11** 12.76* 10.40**
Age of GPs -0.30 -0.25 -0.68 -0.42 -0.66
Proportion of female GPs 3.63 10.41 3.38 17.84 2.96
Patient sex (proportion of females) -66.25 -57.20 -59.90 -32.46
Patient age (proportion 68+) 44.46 50.03 24.84 12.75
RUB proportions
RUB 1 -127.0 -96.43 6.311
RUB 2 103.3 96.19 208.5
RUB 3 -15.47 53.23 223.1
RUB 4 -596.2** -500.5 -274.7
RUB 5 -704.9* -565.4 -43.02
ICPC-2 chapter proportions
A General and unspecified -10.34
B Blood/immune system -201.6
D Digestive -151.1
F Eye -122.3
H Ear 199.6
K Cardiovascular -11.75
L Musculoskeletal -43.20
N Neurological 141.5
P Psychological -88.09
R Respiratory -84.22
S Skin 68.11
T Endocrine/Metabolic and Nutritional 47.97
U Urological -4.391
W Pregnancy and Family Planning -686.9
X Female Genital -23.40
Y Male genital -383.6
Z Social Problems 151.2
ICPC-2 chapter component proportions
Process codes 11.11
Symptoms/complaints -175.4**
Infections -117.3
Neoplasms 7.581
Injuries 107.0
Congenital anomalies -597.9
Other diagnoses -104.7
Constant -15.05 -1.176 40.12 60.66 93.93
N 59 59 59 59 59
R2 0.126 0.142 0.414 0.553 0.521
R2 a 0.0780 0.0608 0.291 0.164 0.323
F 4.901 3.362 3.993 2.992 6.245
* p < 0.05, ** p < 0.01, *** p < 0.001
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incentive for physicians to provide more treatments, be-
cause payment is dependent on the quantity of care, rather
than quality of care. Similarly, when patients are shielded
from paying (cost-sharing) by health insurance coverage,
they are incentivized to welcome any medical service that
might do some good. FFS might discourage efficiency of
integrated care, and a variety of reform efforts have been
attempted, recommended, or initiated to reduce its influ-
ence (such as moving towards bundled payments and capi-
tation). In capitation, physicians are discouraged from
performing procedures, including necessary ones, because
they are not paid anything extra for performing them.
Prior to potential reforms of the remuneration system,
it is relevant to investigate the extent to which public re-
sources are allocated according to morbidity status. Pre-
vious studies focusing on all types of general practice
patients concluded that morbidity measures were signifi-
cant patient-related fee-for-service (FFS) expenditure
drivers [15–17, 29]. Morbidity characteristics explained
18–31 %, age and gender 13 % and volume of activity ex-
plained about 35 % of the resource allocation through
FFS. Regardless of what chronic disease a patient might
suffer from, then a recent study revealed, that multimor-
bidity was generally associated with greater outpatient
and inpatient utilization, and, increased multisystem
multimorbidity was associated with a higher outpatient
share of total costs but a lower inpatient share of total
costs [30]. A study of patients diagnosed with type 2 dia-
betes has demonstrated expenditures to increase pro-
gressively with the patients’ degree of comorbidity and
being higher for patients who suffered from diagnostic
markers. For diabetes type 2 patients a total of 17–25 %
of the expenditure variation was explained by age, gen-
der and patients’ comorbidity patterns, and type 2 dia-
betes patient comorbidity characteristics are significant
patient-related FFS expenditure drivers in diabetes care
[10]. The association between FFS expenditure and co-
morbidity burdens for COPD in our study appears to be
at the same level as for diabetes type 2 and comorbidity
[10]. In addition to missing morbidity adjustment, the
FFS component may be too dominant in Denmark [23].
The reason for a lower expenditure variation among pa-
tients with diabetes compared to the overall GP visits
not relating to a chronic disease could be that GPs actu-
ally do take care of more than one condition for each
visit and are thus more efficient, this way reducing the
total number of visits each patient has to the GP.
Alternatively, another explanation could be that patients
diagnosed with diabetes often have more diagnoses that
are actually a part of the diabetic complex, which is re-
corded in the ICPC coding. Conditions like hyperten-
sion, dyslipidemia and obesity are all part of the diabetic
complex and will thus be likely to disturb the analysis of
the data.
The observed morbidity is one way of estimating needs
for medical service. However, opponents may argue that
the observed morbidity does not say much about how
complicated the patients’ conditions are or how severe
the condition is. GPs at the moment code contacts with
patients to ensure an overview of each patient and thus
enhance the medical quality of care. If the remuneration
system is to change according to resource allocation
bands and make use of diagnostic coding, the GPs’
behavior with regard to coding diagnosis may risk chan-
ging in the pursuit of a higher reimbursement, thus de-
creasing the value of the coding system for the purpose
of quality of care.
Strengths and weaknesses
In 2010, only a limited number of GPs (3–4 %) coded
sufficiently to qualify as sentinel GP clinics. Conse-
quently, the number of clinics for our second-stage ana-
lysis was limited. Sentinel GP clinics coding diagnoses
for more than 70 % of their patients are preferred for re-
search and monitoring. The current sample of patients
was representative of all general practice patients. How-
ever, the sample of 59 sentinel general practice clinics
was not representative of all Danish general practice
clinics. From 2011 it has been mandatory for all GPs in
Denmark to start using the sentinel data capture module
and to use ICPC-2 codes for eight specific conditions: 1)
COPD, 2) asthma, 3) chronic musculoskeletal disorders,
4) osteoporosis, 5) cardiovascular diseases, 6) cancer, 7)
diabetes, and 8) non-psychotic psychiatric diseases. It is
the plan to make use of more ICPC coding to ensure
follow-up and quality of care in general practice. How-
ever, use of these ICPC codes from general practice for
remuneration may lead to gaming among GPs and/or
hamper the quality of the data, and thus the intended
coding for quality purposes. The use of patient-level data
has allowed us to explore the ways in which patient
morbidity measures and related general practice clinic
characteristics explain politically negotiated FFS expen-
ditures. However from a clinical point of view the lack
of adjustment for COPD severity (lung function, exacer-
bation history) and for socioeconomically status of the
patients is a drawback, and might be able to explain fur-
ther variation in the expenditures.
Patient-level analysis makes use of much more infor-
mation about patients than general practice clinic-level
analysis. A feature of the included sentinel general prac-
tice clinics is that they coded diagnoses on a voluntary
basis in 2010. So far, no economic incentives have been
agreed upon to do this. Nevertheless, it is still possible
that the quality of diagnosis coding needs to be im-
proved. Care should be taken when combining clinical
diagnoses with economic incentives; the latter may very
well distort the coding system. We argue that physicians
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in sentinel general practice clinics have been trained in
coding and that they code more than 70 % of their con-
tacts with patients. Danish sentinel general practice
clinics code most chronic diseases such as diabetes and
chronic obstructive pulmonary disease in a valid and re-
liable way. A weakness of analyzing cost drivers using
retrospective FFS data as a way to guide remuneration
reforms is that the dataset by definition mimics the state
that needs reform. If for example the current remuner-
ation schemes does not adequately incentivize appropri-
ate treatment for high need patients then the dataset
may not reveal the variation in need that is actually
present. Therefore retrospective variation analysis should
be complemented with other analysis to reform remuner-
ations schemes. A previous study tries to select subgroups
of FFS services that may be thought of as candidates to be
substituted with capitation. The problem with this ap-
proach is however that there is no good guidance for how
to estimate patient need [31].
Conclusion
This study found that age, gender, and comorbidity char-
acteristics were significant patient-related FFS expenditure
drivers for patients diagnosed with COPD in general prac-
tice clinics. A higher number of GPs per clinic increases
expenditure per patient diagnosed with COPD, indicating
that larger general practice clinics may be able to exploit
economies of scale. Further studies with more clinics and
patients included are recommended. Our results, however,
may indicate that there is room for improvement of the
association between politically negotiated FFS expendi-
tures and comorbidity among patients with COPD in GP
clinics.
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